GL0034
Phase 2Small molecule
Sun Pharmaceutical Industries LimitedGL0034 is one of 79 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
113 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Precose
BayerApproved
Topamax
WWim Janssens
Approved
Nesina
TakedaApproved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Retatrutide
Eli LillyPhase 3
Zofran
NovartisPhase 2
Combination Therapy
Chong Kun Dang PharmaceuticalPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GL0034. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details